Kepler Capital Markets Reiterates €115.00 Price Target for Merck KGaA (MRK)
Merck KGaA (FRA:MRK) received a €115.00 ($136.90) price objective from Kepler Capital Markets in a report released on Wednesday. The firm presently has a “buy” rating on the healthcare company’s stock. Kepler Capital Markets’ price objective would indicate a potential upside of 25.82% from the stock’s current price.
Several other analysts have also issued reports on the company. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Merck KGaA in a report on Wednesday. Sanford C. Bernstein set a €115.00 ($136.90) target price on Merck KGaA and gave the stock a “buy” rating in a report on Wednesday. UBS Group reissued a “buy” rating on shares of Merck KGaA in a report on Monday. Nord/LB reissued a “neutral” rating on shares of Merck KGaA in a report on Tuesday, January 2nd. Finally, Warburg Research set a €115.00 ($136.90) target price on Merck KGaA and gave the stock a “buy” rating in a report on Wednesday, December 13th. Twelve research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of €107.57 ($128.06).
Merck KGaA (MRK) traded down €1.44 ($1.71) on Wednesday, hitting €91.40 ($108.81). The stock had a trading volume of 280,130 shares. The firm has a market cap of $11,830.00 and a price-to-earnings ratio of 21.41. Merck KGaA has a 12 month low of €87.33 ($103.96) and a 12 month high of €115.00 ($136.90).
COPYRIGHT VIOLATION NOTICE: “Kepler Capital Markets Reiterates €115.00 Price Target for Merck KGaA (MRK)” was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/17/kepler-capital-markets-reiterates-115-00-price-target-for-merck-kgaa-mrk.html.
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.